The Cost of Feasibility: What Questionnaires and Qualification Visits Take From Sites
Published November 2026 — Published research puts the cost to sites of feasibility assessments and qualification visits at $170 million in 2024. This report brings together the available data on how much time the process takes, how much of it is repeated, and what sites get back.
Unpaid Work Before the Study Starts
Before a site is awarded a study, it completes a feasibility questionnaire and often hosts a qualification visit. The work is unpaid, and the site may not be selected. For years the burden was described in anecdotes. There is now enough published data to measure it.
This report draws mainly on a 2024 Tufts CSDD survey of 290 sites, an ASCO task force survey of oncology practices, a 2023 Advarra survey of more than 500 research professionals, and a 2024 consensus paper from a task force of sites, sponsors, and CROs.
Key Findings
Tufts CSDD estimates that the global site community spent $170 million in 2024 completing feasibility assessments and qualification visits for industry-funded trials.
On average, a site completes 15 feasibility assessments and 10 qualification visits a year. Networks and site management organizations handle about twice the feasibility volume.
In the ASCO task force survey of 113 oncology practices, each feasibility questionnaire took four hours on average and each pre-study visit ten.
The same practices reported that questionnaire content repeated information they had already provided in 81% of cases, and that questionnaires were similar between sponsors in 86%.
Tufts found that feasibility takes 29.4 days on average, and that sites wait nearly three times longer for a response than they spend completing the assessment.
Sites receive feedback on 43% of assessments, and about half of those who receive it say it is not useful.
What the Data Shows
Four findings stand out across the sources.
The Burden Is Growing
In the Advarra survey, 49% of sites said the burden of feasibility surveys had increased over five years. In the Tufts survey, 80% reported spending the same or more time than three years earlier. Advarra attributed the burden partly to redundant questions about site capabilities, and found that fewer than a quarter of sites said most surveys included questions specific to the study.
Most of It Is Repetition
The ASCO statement described current methods as burdensome, inefficient, time-consuming, redundant, and resource intensive. It recommended standardized questions and a central portal or universal site profile. A sponsor speaker at a 2025 industry meeting noted that sites may receive preliminary questionnaires for the same trial from three or four competing CROs.
Sites Often Answer Without the Protocol
More than 70% of sites in the Tufts survey want the full protocol at feasibility, but sponsors provide the final protocol for 42.7% of opportunities. The 2024 task force paper recommended that feasibility begin only once the protocol is final or close to it.
Dedicated Teams Do Better
Tufts found that about half of questionnaires from independent sites and academic centers draw follow-up requests, against 21% for sites with a dedicated feasibility team. Most networks have such a team. Most academic centers do not.
A Caution on One Popular Figure
It is often said that a coordinator spends 264 hours a year on feasibility forms. The figure traces to trade reporting on the ASCO survey, where it was a median per responding site across all feasibility work, not an average per coordinator. We have not relied on it here.
What Sites Can Do
Sites cannot redesign the process. They can change how much of it they repeat.
If four in five questions repeat, the answers should be written once and maintained: investigators, equipment, patient population, and performance history in one place.
The Tufts data suggests that sites with a dedicated team get fewer follow-up requests. Even a small site can name one person responsible and route clinical questions to the investigator with a deadline.
Record how many requests you receive, how long each takes, and how many you win. Tufts found sites are selected for about two-thirds of the studies they bid on. Knowing your own rate shows which requests are worth the effort.
Conclusions
The research agrees on the main points. Feasibility is a large, rising, and mostly unpaid cost to sites. Much of the work is repetition. Sites spend more time waiting than answering, and they seldom learn why they were or were not chosen.
Industry efforts to standardize the process have been recommended since at least 2021 and have moved slowly. Until they succeed, the practical gains for a site come from answering the repeated questions once and reusing the answers.
Answer the Repeated Questions Once
FeasComplete™ is built around the problem this research describes. A site sets up its profile once, covering investigators, equipment, therapeutic areas, patient population, and historical performance. When a questionnaire arrives, FeasComplete drafts each response from that profile and fits it to the format the sponsor asks for.
The team then reviews and edits. Individual questions can be assigned to the coordinator, the investigator, or the director, each with a deadline and automatic reminders, and every answer keeps a version history. The site still decides what it says. It no longer retypes it.
This industry report is based on published announcements and industry research. Figures are reported as stated in the sources below and have not been independently verified by Clinitiative. Companies named are not Clinitiative clients unless stated.
- Applied Clinical Trials: Benchmarking the investigative site qualification process (Tufts CSDD, February 2025)
- ASCO task force abstract: Reducing burdens of site feasibility assessments for conducting clinical trials (2020)
- The ASCO Post: New research statement recommends streamlining and standardizing site feasibility assessments (March 2021)
- Advarra: New clinical trial industry survey reveals increased burdens on sites (October 2023)
- Contemporary Clinical Trials Communications: Redefining feasibility in clinical trials (2024)
- Applied Clinical Trials: 2025 SCRS Global Site Solutions Summit: streamlining feasibility for sites
- Applied Clinical Trials: Revamping site feasibility as trials become decentralized (April 2021)
- Clinical Leader: Too little info, too much time wasted: feasibility challenges for sites (January 2026)
See How FeasComplete™ Works
Feasibility responses drafted from your own site profile, reviewed by your team, and submitted in the sponsor's format.